Unique ID issued by UMIN | UMIN000018753 |
---|---|
Receipt number | R000021693 |
Scientific Title | Long term outcome of Endovascular therapy for PAD with intermittent claudication observational prospective multicenter Registry |
Date of disclosure of the study information | 2015/09/28 |
Last modified on | 2019/04/01 20:34:08 |
Long term outcome of Endovascular therapy for PAD with intermittent claudication
observational prospective multicenter Registry
ASHIMORI IC REGISTRY
Long term outcome of Endovascular therapy for PAD with intermittent claudication
observational prospective multicenter Registry
ASHIMORI IC REGISTRY
Japan |
peripheral artery disease with intermittent claudication
Cardiology |
Others
NO
To evalutate the outcome 12 months after Endovascular Treatment(EVT) for PAD patients with claudication. Outcomes are efficacy and safty of EVT and, the efficary includes the patency of index lesion and the change of leg symptoms.
We investigate long term outcome 3years after EVT.
Safety,Efficacy
Primary patency rate of target vessel 12 months after EVT
Improvement of leg symptom 12 months after EVT.
Major adverse events (MAE) occurring within 3years after index treatment. MAE is defined as death, myocardial infarction (Q-wave and non-Q-wave), stroke, TVR, or major amputation of index limb
Improvement of leg symptom assessed by 6 minutes walking test
The change in femoral and the below-knee
circumference
Observational
20 | years-old | <= |
100 | years-old | >= |
Male and Female
1)Patients diagnosed with PAD
2)Patients aged 20 years or older when providing consent
3)Patients providing written consent indicating understanding of and agreement to participate in the study, and willing to undergo follow up at 1, 2, and 3 years after index treatment
4)Patients with an index limb ABI equal to or lower than 0.9, or definite diagnosis of PAD in accordance with ACCF/AHA guidelines if ABI is greater than 0.9.
5)Patients have symptoms including claudication and rest leg pain.
1)Terminally ill patients expected to live less than one year EVT
2)Patients with ischemic ulcer or gangreen
3)Patients with untreated coagulation or significant bleeding disorders and patients unable to receive anticoagulation or antiplatelet treatment
4)Patients who are or may be pregnant or lactating
5)Patients whose treatment side leg has already been amputated above the ankle
6)to participate in other clinical trials that could possible affect the scientific validity of this study
600
1st name | Hiroshi |
Middle name | |
Last name | Ito |
Okayama University
Department of Cardiovaclar medicine
700-8558
2-5-2 SHIKATACHO KITAKU OKAYAMA CITY
086-235-7351
hiromail1979@yahoo.co.jp
1st name | Hironobu |
Middle name | |
Last name | Toda |
Okayama University
Department of Cardiovaclar medicine
700-8558
2-5-2 SHIKATACHO KITAKU OKAYAMA CITY
086-235-7351
hiromail1979@yahoo.co.jp
Okayama University
Department of Cardiovasclar medicine
none
Self funding
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital, Ethics Committee
2-5-1 Shikatatyo Kitaku Okayama City
086-235-6938
mae6605@adm.okayama-u.ac.jp
NO
2015 | Year | 09 | Month | 28 | Day |
Unpublished
No longer recruiting
2015 | Year | 09 | Month | 28 | Day |
2015 | Year | 09 | Month | 29 | Day |
2016 | Year | 01 | Month | 01 | Day |
2022 | Year | 03 | Month | 31 | Day |
This study is prospective cohort study.We investigate patients performed EVT from Jan, 2016 to Mar 2021.
2015 | Year | 08 | Month | 21 | Day |
2019 | Year | 04 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021693